Background Molnupiravir is an oral antiviral drug that received Emergency Use
Authorization in three countries for the treatment of mild COVID-19. The aim of this …

Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …

The first two oral antivirals, molnupiravir and nirmatrelvir–ritonavir, are now becoming
available in many countries. These medicines will be indicated to treat mild-to-moderate …

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …

The recent emergence of the SARS-CoV-2 Omicron variant of concern (VOC), which
contains a heavily mutated spike protein capable of escaping preexisting immunity …

Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19
in China due to their earlier approval by the National Medical Products Administration …

Introduction Different antivirals are available for the treatment of outpatients with COVID-19.
Our aim was to describe a real-world experience of outpatient management of COVID-19 …

Background People with immune dysfunction are at higher risk of severe outcomes from
COVID-19 infection, but relatively little epidemiologic information is available for mostly …

To the Editor, In France, the Omicron variant (Pango lineage B. 1.1. 529) accounted for
99.3% of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) diagnoses at the …

Objective To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody)
with molnupiravir (an antiviral) in preventing severe outcomes of covid-19 in adult patients …